The Food and Drug Administration announced the launch of a new program to fast-track agency approvals for drug manufacturers working on products that could cure chronic disease, prepare for a pandemic,

A new pilot program announced by FDA Commissioner Martin Makary would award vouchers that could cut drug reviews to one or two months — but only for products that meet a special criteria.

The U.S. Food and Drug Administration has revealed plans to launch a national priority voucher program aimed at reducing the drug review time period for selected manufacturers. Under this new plan, drug review times will be shortened to just 1 to 2 months,